The shares of one of the Leading Healthcare Groups in India which serves over 25 specialities gained marginally in the day’s trade after it declared an increase of stake in its subsidiary by 5.72 percent thereby increasing its stake to 62.44 percent.
At the day’s closing the shares of Krishna Institute of Medical Sciences Limited were trading at Rs. 1,894.85 up 0.37 percent from its previous day close price and its market capitalization is Rs. 15,178 Crores.
As per the company’s filing, Krishna Institute of Medical Sciences Limited has made an investment in SPANV Medisearch Lifesciences Private Limited (KIMS Kingway), by acquiring additional 5.72 percent stake in it for a consideration of Rs. 22,19,90,000 (~Rs. 22.20 Crores). The Shares were acquired at Rs. 221.99 per equity share.
KIMS has increased its holding from 56.72 percent to 62.44 percent which is an increase of 5.72 percent in KIMS Kingsway. Krishna Institute of Medical Sciences(KIMS) is the holding company of SPANV Medisearch Lifesciences Private Limited (KIMS Kingway).
The company’s revenue grew 33.13 percent from Rs. 1,650.83 crores in FY22 to Rs. 2,197.68 Crores in FY23, accompanied by increasing profits of Rs. 332.69 Crores to Rs. 336.32 Crores.
IN FY23 it has reported a return on equity (ROE) of 23.93 percent and a return on capital employed (ROCE) of 27.84 percent, it is making good returns on its equity and capital employed.
According to the latest shareholding data available for the September 2023 quarter, the company’s Promoters hold 38.84 percent stake, the Domestic Institutional Investors hold 34.81 percent and the Foreign Institutional Investors (FII) hold 14.24 percent.
Krishna Institute of medical sciences is one of the leading and well known Multi Specialty Hospital which serves over 25 specialties Including oncology, neurosciences, cardiac sciences etc, with over 10000 personnel comprising doctors, nurses and support staff.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
